Barclays lowered the firm’s price target on Replimune Group to $13 from $50 and keeps an Overweight rating on the shares. The analyst “derisked” the model to reflect the failure of Replimune’s pivotal study in cutaneous squamous cell carcinoma and pipeline prioritization. However, the firm see upsides with stock trading at one-times cash.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on REPL:
- Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers
- Replimune Group price target lowered to $38 from $42 at JPMorgan
- Replimune Group put volume heavy and directionally bearish
- Replimune Group price target lowered to $48 from $50 at H.C. Wainwright
- Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research
